1. Home
  2. CRI vs ZYME Comparison

CRI vs ZYME Comparison

Compare CRI & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carter's Inc.

CRI

Carter's Inc.

N/A

Current Price

$37.43

Market Cap

1.5B

ML Signal

N/A

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

N/A

Current Price

$27.66

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CRI
ZYME
Founded
1865
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2002
2022

Fundamental Metrics

Financial Performance
Metric
CRI
ZYME
Price
$37.43
$27.66
Analyst Decision
Hold
Strong Buy
Analyst Count
6
11
Target Price
$35.60
$38.90
AVG Volume (30 Days)
1.0M
430.7K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
2.74%
N/A
EPS Growth
N/A
33.33
EPS
3.26
N/A
Revenue
$2,898,426,000.00
$105,965,000.00
Revenue This Year
$4.57
$183.10
Revenue Next Year
$1.12
N/A
P/E Ratio
$11.52
N/A
Revenue Growth
1.91
38.87
52 Week Low
$24.71
$13.60
52 Week High
$44.44
$29.75

Technical Indicators

Market Signals
Indicator
CRI
ZYME
Relative Strength Index (RSI) 40.87 69.73
Support Level $37.18 $22.10
Resistance Level $39.16 $28.49
Average True Range (ATR) 1.40 1.02
MACD -0.20 0.46
Stochastic Oscillator 37.29 93.46

Price Performance

Historical Comparison
CRI
ZYME

About CRI Carter's Inc.

Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: